Skip to Main Content

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Conditions

Diseases of the Lung | Diseases of the Respiratory Systems

Phase III

What is the purpose of this trial?

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Start Date
    04/02/2021
  • End Date
    11/12/2023

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/02/2022
  • Study HIC
    #2000029265